Please assess the completion status of the following clinical trial:

Trial Title: Study of Debio 1450 for Bacterial Skin Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Has clinically documented infection of the skin or skin structure suspected or documented to be caused by a staphylococcal pathogen~* Meets other protocol-specified criteria for qualification and contraception~* Is willing and able to remain confined in the study unit for the entire duration of each treatment period and comply with restrictions related to food, drink and medications~* Voluntarily consents to participate and provides written informed consent prior to any protocol-specific procedures~Exclusion Criteria:~* Has history or current use of over-the-counter medications, dietary supplements, or drugs (including nicotine and alcohol) outside protocol-specified parameters~* Has signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise:~  1. the safety or well-being of the participant or study staff;~ 2. the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding);~ 3. the analysis of results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Debio 1450 320/480 mg (Type: EXPERIMENTAL): After 2 doses of Debio 1450 IV (intravenous) therapy, the Debio 1450 320/480 mg daily dose group receives 240 mg Debio 1450 Oral + Linezolid Placebo twice daily (BID).
- Debio 1450 160/240 mg (Type: EXPERIMENTAL): After 2 doses of Debio 1450 IV therapy, the Debio 1450 160/240 mg daily dose group receives 120 mg Debio 1450 Oral + Debio 1450 Oral Placebo + Linezolid Placebo BID.
- Placebo (Type: PLACEBO_COMPARATOR): After 2 doses of Vancomycin IV, the Placebo comparator group receives Debio 1450 Oral Placebo + Linezolid 600 mg BID.

Based on this trial design, predict the completion outcome and termination type (if applicable).